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Case scenario
A 3 year old boy presented with a 3 week history of nasal 
obstruction, clear rhinorrhea, difficulty with feeding and a 
productive cough.  Child was afebrile, had occasional watery 
itchy eyes and mother claimed that at night he tended to wake up 
a couple of times coughing and crying.   He suffered from eczema 
as a baby.  On examination he had clear rhinorrhoea, nasal 
mucosa appeared red, ear drums looked slightly pink, tonsils 
swollen yet normal colour, cervical lymph nodes absent.  
Introduction
Rhinitis is inflammation of the nasal mucosa producing 
rhinorrhoea, sneezing, nasal congestion, nasal pruritis and post 
nasal drip.  It is often accompanied by symptoms involving the 
eyes, ears and throat.1 Rhinitis can be classified by aetiology into 
allergic and non-allergic. Allergic rhinitis can be intermittent, 
persistent, or occupational.2 The most common cause of non-
allergic rhinitis is infection that can be acute or chronic. Other 
types of non-allergic rhinitis are described in Figure 1.3,4
Rhinitis is a very common disease and results in a significant 
number of GP consultations.  The two most common forms of 
rhinitis a GP encounters are allergic rhinitis and rhinitis due to 
viral illness.  It is a well known fact that the global prevalence 
of allergic rhinitis has been on the increase and Malta has 
shown a similar trend.5 The peak prevalence of allergic rhinitis 
is observed in children and young adults. Prevalence estimates 
range from 10 to 30 percent of adults and up to 40 percent of 
children, making allergic rhinitis currently the most common 
chronic condition found in children. Malta was one of the centres 
that participated in The International Study of Asthma and 
Allergies in Childhood (ISAAC) and from this study it resulted 
that Malta had the second highest cumulative prevalence rate 
of allergic rhinitis in the world.6
Although rhinitis may appear to be a trivial illness it can 
cause a significant degree of morbidity.  Rhinitis can alter 
the social life of patients,7 affect school performance,8 impair 
cognitive function,9 work productivity10 and has significant 
implication on costs.11 Furthermore rhinitis is associated with 
a number of other co-morbidities, such as asthma, sinusitis,12 
sleep disturbance13 etc. Up to 40% of patients with allergic 
rhinitis also have asthma and up to 80% of patients with asthma 
experience nasal symptoms. Furthermore, patients with allergic 
rhinitis have three times the risk of developing asthma compared 
with those without allergic rhinitis. Children who develop 
rhinitis within the first year of life have twice as much chance 
of developing asthma compared to those who develop rhinitis 
later in life. Treating allergic rhinitis has beneficial effects on 
asthma, suggesting that upper airway disease is a risk factor 
for asthma.14-16
Aetiology
Over the past years, increasing number of studies support 
the fact that the pathophysiology of allergic rhinitis and asthma 
share the same mechanisms “one airway, one disease” (the 
unifying theory).17-19 Allergic rhinitis, like asthma, is thought to 
be the result of an IgE-mediated reversible inflammation of the 
nasal mucosa that occurs on exposure to allergens.  Risk factors 
for allergic rhinitis include: 
• family history of atopy 
• serum IgE > 100 IU/mL before age 6 
• higher socioeconomic class 
• exposure to indoor allergens such as animals and dust 
mites
• presence of a positive allergy skin prick test.20
42 Malta Medical Journal    Volume 19   Issue 03   September 2007
People of a high socioeconomic class tend to be exposed to 
less “dirt” and microbes when young. Together with a genetic 
predisposition (atopy) this provides the perfect combination 
for predominance of Th2 cells over Th1 cells.  Such individuals 
will develop allergic diseases on exposure to indoor allergens 
at a later age – The Hygiene Hypothesis.21 Th2 cells promote 
the production of IgE antibodies that interact with mast cells 
and basophils to produce the acute-phase response resulting 
in sneezing, congestion and/or rhinorrhea.  A late-phase 
response then peaks after 6-12 hours resulting mainly in 
nasal obstruction.22  Aeroallergens include pollen and mould 
for intermittent allergic rhinitis, and for persistent rhinitis 
allergens include house dust mites, moulds, animal allergens, 
cockroaches, certain occupational allergens, as well as pollen in 
areas where pollen is prevalent perennially.14,20
Although the symptoms of allergic and non-allergic rhinitis 
overlap significantly, the causes appear to be entirely different.1 
Infective rhinitis is usually due to one of a large number of 
viruses (e.g. Rhinovirus), and bacterial infection is usually 
a secondary complication.23 The pathophysiology of NARES 
(non-allergic rhinitis with eosinophilia syndrome) is poorly 
understood, but a key component involves a self-perpetuating, 
chronic eosinophilic nasal inflammation with development of 
nasal micropolyposis and polyposis. Mast cells are likely to 
play an important role as well. NARES is a risk factor for the 
development of nasal polyposis and aspirin sensitivity, as well 
as obstructive sleep apnoea.24 Unlike NARES, in vasomotor 
rhinitis there are no abundant eosinophils in the nasal mucosa 
and current theories for vasomotor rhinitis include increased 
cholinergic glandular secretary activity (for runners; have 
mainly rhinorrhea), and nociceptive neurons with heightened 
sensitivity to usually innocent stimuli (for dry patients; have 
mainly nasal obstruction).23 
In both allergic and non-allergic rhinitis once an 
inflammatory process is set in, one ends up with non-specific 
nasal hyperreactivity: there is an increased nasal response to 
normal stimuli resulting in sneezing, nasal congestion and/or 
secretion.14
Diagnosis
Differentiating allergic rhinitis from other causes of rhinitis 
can be difficult because the diagnostic criteria for various 
forms of rhinitis are not always clear-cut.25 To date most of 
the literature has focused on the diagnosis and management 
of allergic rhinitis.  Recommendations for specific diagnostic 
criteria and treatment options for non-allergic rhinitis are 
often lacking compared with those addressing allergic rhinitis.26 
Accurate diagnosis is important because therapies that are 
effective for allergic rhinitis (i.e. antihistamines) may be less 
effective for other types of rhinitis.27
To complicate things further, it is known that a number 
of people suffer from a combination of allergic and non-
allergic rhinitis. Research shows that the prevalence of pure 
allergic rhinitis in the adult population with symptoms is 
43%, combination allergic rhinitis and non-allergic rhinitis is 
34%, and pure non-allergic rhinitis is 23%.28 A study in Malta 
involving 415 patients presenting with rhinitis of 3 months 
duration showed that 55% of the patients were atopic and 
common allergens involved house dust mite, cat dander and 
grass pollen. Skin test-negative patients with idiopathic rhinitis 
were mostly females and tended to present a decade later.5
When one is dealing with a patient with rhinitis, a detailed 
history and focused physical examination are essential for 
the correct assessment and management of the patient25 
(Figure 1).20,22,29,30  Furthermore, it is important that one 
enquires into the impact the condition has on the patient’s life 
Conditions that may mimic rhinitis
• Inflammatory or immunologic conditions 
 e.g. Wegener’s granulomatosis
• Cerebrospinal fluid rhinorrhea (previous head injury)
• Ciliary defects
• Structural or mechanical conditions e.g. choanal 
atresia, deviated nasal septum, enlarged adenoids, 
foreign bodies (especially children), nasal tumours
Signs and symptoms associated 
with the above conditions
History
• Unilateral nasal obstruction and/or unilateral 
rhinorrhea, 
• Nasal bleeding 
• Decreased sensation of face, palate and teeth 
• Previous head trauma and clear rhinorrhea 
• Ulcerative lesion in nose
• Past history of trauma to the Nose
Examination
• Deviated nasal septum
• Visible nasal polyps/foreign body
Table 1: Conditions that may mimic rhinitis and 
their signs and symptoms
Classification Definition
Intermittent Occurs 4 days or less per week or 
for less than 4 weeks
Persistent Occur more than 4 days per week 
and for more than 4 weeks
Mild All of the following: normal sleep; 
normal daily activities, sport, 
leisure; normal work and school; 
symptoms not troublesome
Moderate-severe One or more of the following: 
abnormal sleep; impairment of 
daily activities, sport, leisure; 
problems caused at work or school; 
troublesome symptoms
Table 2: Classification of allergic rhinitis22
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and what are the patient’s expectations from treatment. One 
should always ask what medications the patient has already tried 
as most patients would tend to have already used a number of 
over the counter medications.  
It is always important to keep in mind that there are a 
number of conditions that can mimic rhinitis.  Even though 
these tend not to be that common it is important to consider 
these especially when patients present with certain signs and 
symptoms (see Table 1).23,31  
Investigation
Investigations for rhinitis are carried out in a situation 
when: 
• diagnosis is uncertain and symptoms are severe 
• patient is not responding to empirical treatment 
• identification of allergen is intended to direct allergen 
avoidance or immunotherapy.22,32
Empiric treatment is appropriate in patients with classic 
symptoms, or in patients with an unclear diagnosis who yet 
have mild symptoms.32
The diagnosis of allergic disease depends on identifying both 
the symptoms occurring on allergen exposure and the relevant 
allergen-specific test.33 The most common diagnostic tests for 
identifying atopy and the particular allergen/s involved are 
the skin test and the allergen-specific immunoglobulin E (IgE) 
antibody test. Other diagnostic tools used in rhinitis include 
nasal provocation testing, nasal cytology (e.g., blown secretions, 
scraping, lavage, and biopsy), imaging (X-ray, CT, MRI) and 
nasolaryngoscopy.
Skin Testing
Skin testing involves introducing (percutanously or 
intradermally) controlled amounts of allergen and control 
substances into the skin.  A positive test will produce a classic 
weal reaction that is compared with controls.
Allergen-specific IgE antibody testing 
(radioallergosorbent testing [RAST])
A raised total blood IgE suggests allergic disease but this 
result is non-specific.34 RAST on the other hand is highly specific 
but generally not as sensitive as skin testing and is more costly.27 
It is recommended when skin testing is not practical or available, 
when patients are taking medications that interfere with skin 
testing (e.g. tricyclic antidepressants, antihistamines) or when 
skin testing is contraindicated33 (e.g. severe eczema).35,36
Nasal endoscopy 
This can detect nasal and sinus pathology that is not 
detectable with a nasal speculum. Referral for nasal endoscopy 
is indicated when symptoms persist despite treatment. It is also 
indicated for the assessment of nasal polyps, crusting high in 
the nasal cavity, serosanguinous discharge, acute and chronic 
rhinosinusitis and nasal perforations and ulceration.
Management
The management of rhinitis can be divided into four main 
categories:14
1. Avoidance of inciting factor, whether allergens or irritants
2. Pharmacological therapy
3. Immunotherapy for allergic rhinitis
4. Patient education
Type of   Alternative or   
allergic rhinitis First-line treatments add-on treatments* Comment 
Mild intermittent Oral antihistamines, Intranasal decongestants Allergen avoidance may eliminate
 Intranasal antihistamines  need for drugs
Mild persistent or  Oral antihistamines, Intranasal decongestants, Sodium cromoglycate useful alternative
is a moderate-severe Intranasal  Sodium cromoglycate to antihistamines and corticosteroids,
intermittent corticosteroids (CS)    especially in children
 (preferred when persistent   
 disease), intranasal   
 antihistamines
Moderate-severe Intranasal CS Oral antihistamines, Ipratropium bromide useful for
persistent  intranasal antihistamines persistent runny nose. Leukotriene
  (if sneeze and itch antagonists may be useful if there is
  predominant), coexisting asthma. If nasal obstruction
  sodium cromoglycate, predominant try decongestant or
  Ipratropium bromide oral CS for short term if it fails
  (if rhinorrhea predominant), consider surgical referral
  Leukotriene antagonists†
* These drugs should usually be used if initial treatment alone has proved ineffective, although they may be used first 
   if standard first-line drugs are unsuitable or contraindicated.  
† Not licensed for use in allergic rhinitis
Table 3: Treatment options for allergic rhinitis
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1. Avoidance of inciting factors
Inciting factors can be divided into aeroallergens in people 
with allergic rhinitis and irritating factors in all types of non-
allergic rhinitis.  When it comes to aeroallergen avoidance, 
it is common opinion that one should consider undergoing 
antigen testing before committing the patient to the expenses 
and burden of certain allergen avoidance methods.31 Allergen 
avoidance should be targeted towards those allergens the patient 
has tested positive to.  The World Allergy Organisation (WAO) 
has issued a patient information sheet describing different 
methods of allergen avoidance.37 Furthermore WAO together 
with WHO have issued guidelines on primary, secondary and 
tertiary prevention of atopy such as breast feeding till 6 months 
of age and parental smoking avoidance during pregnancy and 
early childhood, in the case of primary prevention.37 Even though 
all the current rhinitis guidelines now suggest that allergen 
avoidance, including house mites, should be an integral part of 
a management strategy, more data is needed to fully appreciate 
the value of allergen avoidance.14 Some recent studies regarding 
house dust mite avoidance (including a meta analysis) question 
the benefits of house dust mite avoidance methods.38,39 In the 
case of non-allergic rhinitis, it is important that the patient 
learns what factors make their rhinitis worse and tries to avoid 
them, such as removal of a drug in drug-induced rhinitis, 
correction of endocrine abnormality in hormonal induced 
rhinitis and avoidance of irritants in vasomotor rhinitis.
2. Pharmacological therapy
Due to the chronicity of most forms of rhinitis, most patients 
will need to take their medications either all year round or else 
Figure 1: Differentiating between different types of rhinitis
Non-allergic
(see Non-allergic box)
Allergic
(see Allergic box)
Mixed type of uncertain
diagnosis. Consider
performing investigation
Further classified into intermittent or 
persistent and mild or moderate-severe
(see Table 2)
Chronic rhinitis Infective cause
Symptoms
•  Clear nasal secretion that 
becomes thick and discoloured
Physical examination
• Lymphadenopathy
• Fever
• Acutely inflamed tonsils
Acute symptoms (one week or less)
After managing as viral illness, 
symptoms last longer than one week?
Acute exacerbation of chronic 
rhintis or a condition in Table 1
Bacterial super
infection / sinusitis
or alternate diagnosis
Viral illness
confirmed
YesNo
YesNo
Yes No
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Allergic rhinitis
• Family history of atopy (eczema,  allergic rhinitis, 
asthma)
• Atopic march (eczema/food allergy, asthma, 
rhinitis/conjunctivitis)
• Symptoms occur on exposure to common known 
antigens with seasonal or exposure variation
• Nasal and palatal itch and paroxysm of sneezing
• Clear rhinorrhea
• Nasal congestion
• Allergic conjunctivitis
• Age of onset below 20
• Malaise, headache and fatigue
• Symptoms related to work (allergic occupational 
rhinitis)
Physical examination
In general practice, the nose can be examined 
with an auriscope fitted with the largest speculum
• Allergic shiners (blue-grey or purple discoloration 
under the lower eyelids)
• Allergic salut and transverse nasal crease
• Adenoid facies
• Wheezing in chest (asthma)
• Eczema
• Throat – in allergic rhinitis post-nasal drip is 
usually not prominent
• Nasal polyps uncommon
Investigation
• Positive skin test and IgE tests to common 
allergens
Non-allergic rhinitis
Diagnosis mainly based on excluding allergic rhinitis
1. Congestion rather than rhinorrhoea/sneezing
2. No FH of Atopy
3. Prominent post nasal drip and enlarged tonsil
4. Usually perennial yet variations can occur with weather 
changes/irritant exposure
5. Negative skin tests and normal IgE concentrations.
Some specific points on particular types 
of non-allergic rhinitis:
• NARES: Eosinophilic infiltration on nasal cytology. 
Sneezing paroxysms, profuse watery runny nose, nasal 
pruritus, occasional loss of smell. Associated with non-
IgE mediated asthma, aspirin intolerance, nasal polyps.
• Vasomotor rhinitis: Most develop rhinitis 
(congestion and hyper secretion mainly) in response 
to environmental conditions, such as cold air, high 
humidity, strong odours, and inhaled irritants. 
Diagnosed through exclusion of all other types of 
rhinitis.
• Hormonal rhinitis: pregnancy, puberty, the use of 
OCP, and hypothyroidism may all be associated with 
nasal obstruction and discharge.
• Drug-induced rhinitis may be caused by several 
drugs, including ACE, beta-blockers, and OCP, Aspirin 
and NSAIDS. Use of intranasal decongestants for more 
than 5–7 days may cause rhinitis medicamentosa.
• Occupational rhinitis: symptoms which are 
temporally related to exposure at work and which 
improve away from the workplace.
Key: ACE = Angiotensin converting enzyme inhibitor, NARES = Non-allergic rhinitis with eosinophilia syndrome,  
NSAIDS = Non-steroidal anti-inflammatory drugs, OCP = oral contraceptive pill
Figure 1 continued: Acute symptoms (one week or less)
during certain periods of the year.  Pharmacological therapy can 
either be given orally or intranasally.  Intranasal treatment has 
the advantage that high concentrations are delivered directly 
to the nose thus reducing systemic side effects.  Yet at times 
delivery is suboptimal and intranasal treatment does little to 
improve other associated symptoms such as conjunctivitis.14 
There are a number of pharmacological options 
available:14,31,40 
• Oral/intranasal antihistamines
• Intranasal corticosteroids
• Oral/intranasal decongestants
• Intranasal sodium cromoglycate
• Intranasal anticholinergics
• Leukotriene antagonists
• Oral corticosteroids
The choice of a particular treatment or combination 
depends on the type of rhinitis being diagnosed, on the severity 
of symptoms and on patients’ expectations and preferences 
(see Table 314,22 for Allergic Rhinitis and Table 420,24,27,41-45 for 
non-allergic rhinitis).  In certain situations treatment can be 
taken on demand, e.g. taking an antihistamine before visiting 
someone that has pets.  Also in very severe cases one can use a 
short course (maximum 2 weeks) of oral steroids as a last resort. 
This will provide quick relief of symptoms and will also clear 
nasal blockage thus allowing better penetration of intranasal 
treatment. 22
3. Immunotherapy
This modality of treatment only applies for allergic rhinitis. 
Allergen-specific immunotherapy can be either given by the 
subcutaneous or sublingual route (SLIT).  It requires 3 or more 
years of treatment and subcutaneous immunotherapy carries 
the risk of anaphylaxis. This treatment modality is intended for 
patients that suffer from allergic rhinitis with demonstrable IgE 
mediated disease.46 It is recommended in patients who have had 
a long duration of symptoms; or in whom pharmacotherapy has 
been partially or totally ineffective or induced side-effects; or in 
patients who do not want to take treatment long term.14 It is most 
effective for house-dust mite, pollen and cat allergy.47 Sublingual 
immunotherapy (SLIT) is effective in reducing rhinitis symptom 
scores and anti-allergic medication requirements compared to 
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placebo. There is insufficient evidence comparing it to injection 
immunotherapy to quantify the treatment effect.22  It is suitable 
for people with mite or pollen allergies who have had a systemic 
reaction to injection immunotherapy or who do not wish to 
have an injection.14 
What is on the horizon?
Apart from the continuous effort by the industry to develop 
better antihistamines, topical corticosteroids and other small 
molecules, there appear not to be any novel drug treatments for 
rhinitis ‘around the corner.’ The most exciting future therapies 
are safe and effective new vaccinations and all are essentially 
improvements on traditional desensitisation injections.48
The anti-IgE monocolonal antibody Omalizumab has been 
shown to be effective in the treatment of allergic rhinitis49,50 and 
asthma, yet its cost is still too high.  However, it does promise to 
offer a one in all solution for atopic individuals, being effective 
for all forms of atopic disease (i.e. asthma, allergic rhinitis, 
eczema) found in these people.
Conclusion
In a survey of sufferers of allergic rhinitis, 60% of all allergic 
rhinitis patients responded that they are “very interested” 
in finding a new medication and 25% are “constantly” trying 
different medications to find one that “works.” Those who 
were dissatisfied also said their health care provider does not 
understand their allergy treatment needs and does not take their 
allergy symptoms seriously.51
It is essential that GPs have a sound understanding of 
the different forms of rhinitis and all the different treatment 
options available.  They must then take time to understand the 
implication of the condition on their patients’ life, and what are 
the patients’ expectations.  It is important to always keep in mind 
that one is treating the patient rather than the rhinitis itself. 
Thus if a patient is satisfied with symptom control, even though 
not completely symptom free, there is no need of increasing 
or adding medication, as this can only impair compliance and 
add side effects.
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